CGA and neuroblastoma: Concomitantly, a dramatic reduction in cell proliferation rates was observed in the shRNA CgA knockdown cells compared to nonsense control neuroblastoma cells as measured by the CellTiter-Glo® luminescent cell viability assay (Fig. 1D) and BrdU incorporation assay (nonsense versus shRNA CgA, 1.0±0.1 versus 0.6±0.05, P<0.01, Fig. 1E).